Overview

GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy of GV1001 in sequential combination with gemcitabine in locally advanced and metastatic adenocarcinoma of the pancreas.
Phase:
Phase 3
Details
Lead Sponsor:
Pharmexa A/S
Collaborators:
CIRION Central Laboratory
Dorevitch
ICON Clinical Research
INC Research
ORION Clinical Services
Syneos Health
Treatments:
Gemcitabine